Markets:

Overview

News

Currencies

International

Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

32.56 +7.05 (+27.64%)

Streaming Delayed Price Updated: 10:50 AM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 23, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings) ↗

May 14, 2024

Via Benzinga

Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months ↗

May 13, 2024

In the last three months, IBRX outperformed NVDA by over 3x.

Via Talk Markets

LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024 ↗

May 13, 2024

LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Analyst Ratings For Legend Biotech ↗

April 17, 2024

Via Benzinga

Unveiling 9 Analyst Insights On Legend Biotech ↗

April 01, 2024

Via Benzinga

Earnings Preview: Legend Biotech ↗

March 08, 2024

Via Benzinga

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

May 13, 2024

From Legend Biotech Corporation

Via Business Wire

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

April 22, 2024

From Legend Biotech Corporation

Via Business Wire

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗

April 19, 2024

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel

Via Benzinga

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

April 11, 2024

From Legend Biotech Corporation

Via Business Wire

What 4 Analyst Ratings Have To Say About Legend Biotech ↗

March 07, 2024

Via Benzinga

Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population ↗

April 08, 2024

FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration...

Via Benzinga

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

April 05, 2024

From Legend Biotech Corporation

Via Business Wire

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy ↗

March 20, 2024

Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual...

Via Benzinga

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

March 19, 2024

From Legend Biotech Corporation

Via Business Wire

FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer ↗

March 18, 2024

FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &...

Via Benzinga

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

March 15, 2024

From Legend Biotech Corporation

Via Business Wire

FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers ↗

March 13, 2024

Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into...

Via Benzinga

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

Via Benzinga

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

March 11, 2024

From Legend Biotech Corporation

Via Business Wire

Earnings Scheduled For March 11, 2024 ↗

March 11, 2024

Companies Reporting Before The Bell • Ballard Power Systems (NASDAQ:BLDP) is estimated to report quarterly loss at $0.13 per share on revenue of $34.20 million.

Via Benzinga

5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024 ↗

March 09, 2024

Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the...

Via Talk Markets

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley ↗

March 07, 2024

Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.

Via Benzinga

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗

February 24, 2024

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...

Via Talk Markets

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

February 23, 2024

From Legend Biotech Corporation

Via Business Wire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

February 13, 2024

From Legend Biotech Corporation

Via Business Wire

Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment ↗

January 23, 2024

In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.

Via Benzinga

As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗

January 10, 2024

Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.